Il semble qu'il y ait eu une erreur en essayant de charger cette page.
Notre équipe a été informée mais veuillez nous contacter en utilisant le widget support email si le problème persiste.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Revenue Multiple | 96,1x - 106,3x | 101,2x |
| Selected Fwd Revenue Multiple | 25,6x - 28,3x | 26,9x |
| Fair Value | 195.794₩ - 216.234₩ | 206.014₩ |
| Upside | -46,0% - -40,3% | -43,2% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| SK bioscience Co.,Ltd. | A302440 | KOSE:A302440 |
| SK Biopharmaceuticals Co., Ltd. | A326030 | KOSE:A326030 |
| Hugel, Inc. | A145020 | KOSDAQ:A145020 |
| Genome & Company | A314130 | KOSDAQ:A314130 |
| SCM Lifescience Co., Ltd. | A298060 | KOSDAQ:A298060 |
| ALTEOGEN Inc. | A196170 | KOSDAQ:A196170 |
| Select LTM Revenue Multiple | ||||||||
| Benchmark Companies | ||||||||
| A302440 | A326030 | A145020 | A314130 | A298060 | A196170 | |||
| KOSE:A302440 | KOSE:A326030 | KOSDAQ:A145020 | KOSDAQ:A314130 | KOSDAQ:A298060 | KOSDAQ:A196170 | |||
| Historical Revenue Growth | ||||||||
| 5Y CAGR | NM- | 34.6% | 12.8% | 260.1% | 89.1% | 28.6% | ||
| 3Y CAGR | -34.0% | 9.4% | 17.2% | 294.7% | 29.5% | 38.5% | ||
| Latest Twelve Months | -27.6% | 54.3% | 16.7% | 94.1% | 18.6% | 6.6% | ||
| Historical EBIT Profit Margin | ||||||||
| 5 Year Average Margin | -2.3% | -477.5% | 37.9% | -3537.1% | -3240.9% | -26.1% | ||
| Prior Fiscal Year | -3.2% | -10.6% | 36.8% | -385.4% | -1868.3% | -10.1% | ||
| Latest Fiscal Year | -51.7% | 17.6% | 44.6% | -87.2% | -1371.0% | 24.7% | ||
| Latest Twelve Months | -51.7% | 17.6% | 44.6% | -87.2% | -1371.0% | 24.7% | ||
| Current Trading Multiples | ||||||||
| EV / LTM Revenue | 9.51x | 14.13x | 9.40x | 2.73x | 35.72x | 191.69x | ||
| EV / LTM EBIT | -18.4x | 80.3x | 21.1x | -3.1x | -2.6x | 776.1x | ||
| Price / LTM Sales | 11.55x | 14.50x | 10.33x | 2.63x | 28.39x | 192.50x | ||
| Low | Mid | High | ||||||
| Benchmark EV / LTM Revenue | 2.73x | 9.51x | 35.72x | |||||
| Historical EV / LTM Revenue | 58.49x | 95.91x | 191.69x | |||||
| Selected EV / LTM Revenue | 96.15x | 101.21x | 106.27x | |||||
| (x) LTM Revenue | 102,855 | 102,855 | 102,855 | |||||
| (=) Implied Enterprise Value | 9,889,282 | 10,409,770 | 10,930,259 | |||||
| (-) Non-shareholder Claims * | 85,855 | 85,855 | 85,855 | |||||
| (=) Equity Value | 9,975,137 | 10,495,625 | 11,016,114 | |||||
| (/) Shares Outstanding | 53.3 | 53.3 | 53.3 | |||||
| Implied Value Range | 187,167.92 | 196,934.08 | 206,700.23 | |||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 187,167.92 | 196,934.08 | 206,700.23 | 362,500.00 | ||||
| Upside / (Downside) | -48.4% | -45.7% | -43.0% | |||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A302440 | A326030 | A145020 | A314130 | A298060 | A196170 | |
| Enterprise Value | 2,452,523 | 7,604,096 | 3,570,659 | 73,916 | 28,458 | 19,233,626 | |
| (+) Cash & Short Term Investments | 1,158,108 | 324,489 | 423,119 | 80,930 | 920 | 185,253 | |
| (+) Investments & Other | 22,357 | 91,439 | 23,433 | 0 | 0 | 2,654 | |
| (-) Debt | (392,814) | (184,482) | (37,606) | (32,024) | (6,966) | (11,759) | |
| (-) Other Liabilities | (219,887) | (27,711) | (37,029) | (50,753) | 0 | (498) | |
| (-) Preferred Stock | 0 | 0 | 0 | (883) | 0 | (89,796) | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 3,020,288 | 7,807,831 | 3,942,576 | 71,186 | 22,412 | 19,319,481 | |
| (/) Shares Outstanding | 78.3 | 78.3 | 11.0 | 31.1 | 20.5 | 53.3 | |
| Implied Stock Price | 38,550.00 | 99,700.00 | 358,000.00 | 2,290.00 | 1,095.00 | 362,500.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 38,550.00 | 99,700.00 | 358,000.00 | 2,290.00 | 1,095.00 | 362,500.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |